A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Latest Information Update: 20 Feb 2023
At a glance
- Drugs Vebicorvir (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Assembly Biosciences
Most Recent Events
- 15 Nov 2021 Results assessing changes in HBV nucleic acids in patients who continued NrtI treatment following discontinuation of Vebicorvir, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 26 Jun 2021 Results assessing whether any treatment emergent core inhibitor or NrtI substitutions were observed after treatment discontinuation from study 211, presented at The International Liver Congress 2021.
- 26 Jun 2021 Results assessing off-treatment (off-Rx) viral response and safety after VBR + NrtI discontinuation (DC) in Study 211, presented at The International Liver Congress 2021.